Free Trial

Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Recommendation of "Hold" from Brokerages

Health Catalyst logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Health Catalyst an average recommendation of Hold (1 sell, 8 hold, 4 buy) with a 12‑month average price target of $2.7955.
  • Several firms have sharply reduced targets recently—e.g., Wells Fargo to $1.00, Stephens to $2.00 and Cantor Fitzgerald to $3.00—indicating downward revisions to expectations.
  • The stock trades around $1.03 (52‑week range $1.02–$5.06) with a market cap of about $75.8M, a recent EPS miss and negative margins/ROE, and roughly 85% institutional ownership.
  • MarketBeat previews top five stocks to own in June.

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) has earned an average recommendation of "Hold" from the thirteen analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $2.7955.

A number of research firms recently commented on HCAT. Stephens decreased their price objective on Health Catalyst from $3.50 to $2.00 and set an "equal weight" rating on the stock in a research note on Friday, March 13th. Cantor Fitzgerald reduced their target price on Health Catalyst from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Friday, March 13th. Wells Fargo & Company reiterated an "equal weight" rating and set a $1.00 target price (down from $5.00) on shares of Health Catalyst in a research report on Wednesday, March 18th. Citigroup reduced their target price on Health Catalyst from $2.75 to $1.75 and set a "neutral" rating on the stock in a research report on Friday, March 13th. Finally, Stifel Nicolaus reduced their target price on Health Catalyst from $3.75 to $2.00 and set a "hold" rating on the stock in a research report on Friday, March 13th.

Check Out Our Latest Analysis on Health Catalyst

Health Catalyst Stock Down 6.4%

HCAT opened at $1.03 on Thursday. The company has a quick ratio of 1.89, a current ratio of 1.89 and a debt-to-equity ratio of 0.62. The firm has a market cap of $75.80 million, a P/E ratio of -0.41 and a beta of 1.81. Health Catalyst has a 52 week low of $1.02 and a 52 week high of $5.06. The business's fifty day simple moving average is $1.63 and its 200 day simple moving average is $2.30.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). The company had revenue of $74.68 million for the quarter, compared to analyst estimates of $73.99 million. Health Catalyst had a negative net margin of 57.20% and a negative return on equity of 4.30%. As a group, equities research analysts anticipate that Health Catalyst will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

Several large investors have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new position in shares of Health Catalyst in the 4th quarter worth about $25,000. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Health Catalyst in the 3rd quarter worth about $39,000. Cresset Asset Management LLC purchased a new position in shares of Health Catalyst in the 2nd quarter worth about $39,000. FNY Investment Advisers LLC purchased a new position in shares of Health Catalyst in the 3rd quarter worth about $45,000. Finally, Focus Partners Wealth purchased a new position in shares of Health Catalyst in the 1st quarter worth about $46,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

About Health Catalyst

(Get Free Report)

Health Catalyst NASDAQ: HCAT is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst's offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.

Read More

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Health Catalyst Right Now?

Before you consider Health Catalyst, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.

While Health Catalyst currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines